Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 85

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 85
---
 | ​ | ​ | ​ | ​    | $ |          — | ​ | ​ | ​ | ​    | $ |         — | ​ | ​ | ​ | ​    | $ |     31,589 | ​ | ​ |
| Less: Fair Value at Prior Year-End of Stock and Option Awards Forfeited During the Covered Year | ​ | ​ | ​    | $ |          — | ​ | ​ | ​ | ​    | $ |          — | ​ | ​ | ​ | ​    | $ |          — | ​ | ​ | ​ | ​    | $ |         — | ​ | ​ | ​ | ​    | $ |   -165,992 | ​ | ​ |
| Compensation Actually Paid                                                                      | ​ | ​ | ​    | $ |  3,526,611 | ​ | ​ | ​ | ​    | $ |  1,806,206 | ​ | ​ | ​ | ​    | $ |    910,108 | ​ | ​ | ​ | ​    | $ | 1,138,299 | ​ | ​ | ​ | ​    | $ |  1,736,913 | ​ | ​ |

Stock and Option Award Valuations: Stock option grant date fair values are calculated based on the Black- Scholes option pricing model as of the date of grant. Adjustments have been made using stock option fair values

Pacira BioSciences, Inc. 2025 Proxy Statement | 89

TABLE OF CONTENTS Executive Compensation

as of each measurement date using the stock price as of the measurement date and updated assumptions (i.e., expected term, volatility, dividend yield, risk free rate) as of the measurement date. Time-vested RSU grant date fair values are calculated using the stock price as of the date of grant. Adjustments have been made using the stock price as of year-end and as of each date of vest, as applicable.

<div align='center'>**Tabular List of Financial and Non-Financial Performance Measures
Used to Link Compensation Actually Paid to Named Executive Officers
for the Year Ended December 31, 2024 to Company Performance**</div>

| ​ |                                      | ​ | ​ |                                       | ​ |
| ​ | Most Important Financial Measures    | ​ | ​ | Most Important Non-Financial Measures | ​ |
| ​ | Total Net Revenues                   | ​ | ​ | Clinical Development                  | ​ |
| ​ | Operating Expenses and Gross